Madrigal Pharmaceuticals
TX, USA
Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Title: Senior Director, Health Systems West Region: West Reports Into: Executive Director, Health Systems Field Medical Field-Based Medical Leadership Role Summary – The Senior Director (SDHS) serves as a pivotal front-line leader, overseeing all Health Systems (HS) field medical colleagues within their assigned region. This role is primarily focused on...